Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Glycated Albumin Predicts the Effect of Dual and Single Antiplatelet Therapy on Recurrent Stroke
First author：jiejie li,yilong wang
Corresponding author：yongjun wang
essential_information
- Person in charge：jiejie li,yilong wang
- Data Sources： CHANCE
- Number of papers：CHANCE20190145
- Published time：2015-03-03
2015-03-03
Published articles
Journal：neurology
Publication type: Original Contributions
IF(IF): 9.91
PMID: 25740863 Link To Pubmed Full text Download
Background And Purpose
To determine the relationship of glycated albumin (GA) and the recurrence of stroke in patients on either dual or single antiplatelet therapy
Method
The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to antiplatelet therapy of clopidogrel plus aspirin or aspirin alone. A subgroup of 3,044 consecutive patients with baseline GA levels from 73 (64%) prespecified clinical sites was analyzed. Patients were categorized into 2 groups based on GA level of 15.5%, the cut point for development of diabetes. The primary outcome was stroke recurrence during 90-day follow-up. Cox proportional hazards models were used to assess the interaction of GA with randomized antiplatelet therapy on their risk of recurrent stroke.
Conclusion
GA could be a potential biomarker to predict the effects of dual and single antiplatelet therapy in patients with minor stroke or TIA
Main results
Significant interaction of GA levels with the 2 antiplatelet therapy groups was found after adjustment for age, sex, and other conventional confounding factors (p 5 0.009). The interaction remained consistent after further adjustment for history of diabetes (p 5 0.010). In patients with lower GA level, stroke occurred in 5.5% of patients in the clopidogrel–aspirin group, and 12.7% in the aspirin group (adjusted hazard ratio [HR] 0.40; 95%confidence interval [CI] 0.26–0.61; p ,0.001). Furthermore, in patients with elevated GA level, stroke occurred in 9.2% of patients in the clopidogrel–aspirin group, and 11.4%in the aspirin group (adjusted HR 0.79; 95% CI 0.60–1.05; p 5 0.103).